World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
33938
World Ranking
13499
National Ranking
516

Giuseppe Tonini publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Giuseppe Tonini sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 722 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Giuseppe Tonini D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Giuseppe Tonini sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Giuseppe Tonini is affiliated with Università Campus Bio-Medico in Italy and specializes in the field of Medicine, with a strong emphasis on Oncology. Their research portfolio encompasses a range of subfields including Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research, and Molecular Biology.

Their research has contributed to several key topics in cancer study, notably:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies

Giuseppe Tonini's frequent publication venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancers
  • ESMO Open
  • Precision Cancer Medicine

Several recent papers provide insight into the scope and focus of Tonini's research activities:

  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer, 2021, Annals of Oncology
  • Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial, 2023, The Lancet Oncology
  • The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials, 2020, British Journal of Cancer
  • Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples, 2020, Journal of Experimental & Clinical Cancer Research
  • Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study, 2020, Advances in Therapy

Giuseppe Tonini collaborates with several frequent co-authors, including:

  • Bruno Vincenzi
  • Daniele Santini
  • Francesco Pantano
  • Marco Russano
  • Alessio Cortellini

Best Publications

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

    Chiara Cremolini;Fotios Loupakis;Carlotta Antoniotti;Cristiana Lupi

  • Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

    Fotios Loupakis;Chiara Cremolini;Gianluca Masi;Sara Lonardi

  • Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr).

    E. Cacciari;S. Milani;Antonio Balsamo;E. Spada

  • KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    F Loupakis;A Ruzzo;C Cremolini;B Vincenzi

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

    R. Gralla;M. Lichinitser;S. Van der Vegt;H. Sleeboom

  • Gut Microbiota and Cancer: From Pathogenesis to Therapy

    Silvia Vivarelli;Rossella Salemi;Saverio Candido;Luca Falzone

  • PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

    Fotios Loupakis;Luca Pollina;Irene Stasi;Annamaria Ruzzo

  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    D. Miles;J. Gligorov;F. André;D. Cameron

  • Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients

    Daniele Santini;Bruno Vincenzi;Giordano Dicuonzo;Giuseppe Avvisati

  • Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study

    Paolo Maione;Francesco Perrone;Ciro Gallo;Luigi Manzione

  • Italian cross-sectional growth charts for height, weight and BMI (6-20 y).

    E Cacciari;S Milani;A Balsamo;F Dammacco

  • Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

    Annamaria Ruzzo;Francesco Graziano;Fotios Loupakis;Eliana Rulli

  • Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study

    Maurizio Muscaritoli;Simone Lucia;Alessio Farcomeni;Vito Lorusso

  • Pamidronate Induces Modifications of Circulating Angiogenetic Factors in Cancer Patients

    Daniele Santini;Bruno Vincenzi;Giuseppe Avvisati;Giordano Dicuonzo

  • High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

    Daniele Santini;Fotios Loupakis;Bruno Vincenzi;Irene Floriani

  • Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

    T C Mineo;V Ambrogi;A Baldi;C Rabitti

  • Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

    Emanuele Valtorta;Cosimo Martino;Andrea Sartore-Bianchi;Frédérique Penaullt-Llorca

  • Pamidronate (P) induces modifications of circulating angiogenetic factors in cancer patients

    D. Santini;B. Vincenzi;G. Di Cuonzo;F. Battistoni

Frequent Co-Authors

Daniele Santini
Daniele Santini Università Campus Bio-Medico
Bruno Vincenzi
Bruno Vincenzi Università Campus Bio-Medico
Alfredo Falcone
Alfredo Falcone University of Pisa
Antonio Russo
Antonio Russo University of Palermo
Fotios Loupakis
Fotios Loupakis Istituto Oncologico Veneto
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Alfonso Baldi
Alfonso Baldi University of Campania "Luigi Vanvitelli"
Michele Caraglia
Michele Caraglia University of Campania "Luigi Vanvitelli"
Mauro Magnani
Mauro Magnani University of Urbino

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying medicine in the USA opens a variety of rewarding career pathways beyond traditional roles. Many students explore graduate-level healthcare degrees that can be completed online, offering flexibility and often lower costs.

If you're interested in mental health services, consider advancing your qualifications through online psych np programs. These programs prepare nurses for specialized, high-demand roles in psychiatric care.

For those fascinated by leadership and management in healthcare, obtaining a Master's in Healthcare Administration is a popular choice. You can find the cheapest mha programs online to help minimize educational expenses. Be sure to compare options carefully, as mha degree cost can vary significantly by institution.

Finally, advancing your nursing career with a Doctor of Nursing Practice is increasingly accessible. Explore the least expensive dnp programs to maximize your investment as you pursue top clinical leadership positions or influential roles in health policy.

Best Scientists Citing Giuseppe Tonini

Trending Scientists

Recently Published Articles